<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39497519</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2222-1751</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Emerging microbes &amp; infections</Title><ISOAbbreviation>Emerg Microbes Infect</ISOAbbreviation></Journal><ArticleTitle>COVID-19 vaccination modified the effect of nirmatrelvir-ritonavir on post-acute mortality and rehospitalization: a retrospective cohort study.</ArticleTitle><Pagination><StartPage>2421397</StartPage><MedlinePgn>2421397</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">2421397</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1080/22221751.2024.2421397</ELocationID><Abstract><AbstractText>While previous research examined coronavirus disease 2019 (COVID-19) antiviral-vaccine interactions through exploratory subgroup analysis, none specifically designed for examining this interaction or its impact on post-acute outcomes. This study examined the interaction between nirmatrelvir-ritonavir and complete COVID-19 vaccination on reducing the risk of post-acute outcomes among COVID-19 patients. We followed COVID-19 patients hospitalized between 11 March 2022 and 10 October 2023, until 31 October 2023 in Hong Kong. Exposure groups were based on nirmatrelvir-ritonavir usage and vaccination status (fully or not fully vaccinated). Post-acute death and all-cause rehospitalization were the study outcomes. Propensity score weighting was applied to balance covariates among exposure groups, including age, sex, Charlson Comorbidity Index, and concomitant treatments. Multiplicative and additive interactions between nirmatrelvir-ritonavir and vaccination status were assessed. A total of 50,438 COVID-19 patients were included in this study and arranged into four exposure groups. Significant additive interaction on post-acute rehospitalization was observed (relative excess risk, 0.10; 95% CI, 0.02-0.19; <i>p</i>-value, 0.018; attributable proportion, 0.07; 95% CI, 0.01-0.12; <i>p</i>-value, 0.017; synergy index, 1.26; 95% CI, 1.02-1.55; <i>p</i>-value, 0.032). The interaction on post-acute mortality was marginally significant. In the subgroup analysis, the interaction effect is more pronounced in older adults, female, and CoronaVac recipients. In conclusion, our study demonstrated an additive interaction between nirmatrelvir-ritonavir and complete vaccination on post-acute outcomes, suggesting greater long-term benefits of the antiviral for fully vaccinated individuals compared to not fully vaccinated patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Huwen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wei</LastName><ForeName>Yuchen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Guozhang</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boyer</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Katherine Min</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Center for Communicable Disease Dynamics, Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hung</LastName><ForeName>Chi Tim</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Xiaoting</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Conglu</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yam</LastName><ForeName>Carrie Ho Kwan</ForeName><Initials>CHK</Initials><AffiliationInfo><Affiliation>School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chow</LastName><ForeName>Tsz Yu</ForeName><Initials>TY</Initials><AffiliationInfo><Affiliation>School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yawen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Landscape Architecture, Department of Architecture, Faculty of Architecture, The University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Shi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Public Health, Tianjin Medical University, Tianjin, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Zihao</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Kehang</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Aimin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medicine &amp; Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mok</LastName><ForeName>Chris Ka Pun</ForeName><Initials>CKP</Initials><AffiliationInfo><Affiliation>Li Ka Shing Institute of Health Sciences, Chinese University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hui</LastName><ForeName>David S C</ForeName><Initials>DSC</Initials><AffiliationInfo><Affiliation>S.H. Ho Research Centre for Infectious Diseases, Chinese University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chong</LastName><ForeName>Ka Chun</ForeName><Initials>KC</Initials><Identifier Source="ORCID">0000-0001-5610-1298</Identifier><AffiliationInfo><Affiliation>School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yeoh</LastName><ForeName>Eng Kiong</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Emerg Microbes Infect</MedlineTA><NlmUniqueID>101594885</NlmUniqueID><ISSNLinking>2222-1751</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>O3J8G9O825</RegistryNumber><NameOfSubstance UI="D019438">Ritonavir</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>2494G1JF75</RegistryNumber><NameOfSubstance UI="D061466">Lopinavir</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019438" MajorTopicYN="Y">Ritonavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="Y">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006723" MajorTopicYN="N" Type="Geographic">Hong Kong</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061466" MajorTopicYN="N">Lopinavir</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010359" MajorTopicYN="N">Patient Readmission</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Paxlovid</Keyword><Keyword MajorTopicYN="N">antiviral</Keyword><Keyword MajorTopicYN="N">interaction</Keyword><Keyword MajorTopicYN="N">long covid</Keyword><Keyword MajorTopicYN="N">post-covid</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the author(s).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>5</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>5</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>5</Day><Hour>2</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>11</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39497519</ArticleId><ArticleId IdType="doi">10.1080/22221751.2024.2421397</ArticleId><ArticleId IdType="pmc">PMC11539398</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hastie CE, Lowe DJ, McAuley A, et al. . True prevalence of long-COVID in a nationwide, population cohort study. Nat Commun. 2023;14(1):7892. doi:10.1038/s41467-023-43661-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-43661-w</ArticleId><ArticleId IdType="pmc">PMC10689486</ArticleId><ArticleId IdType="pubmed">38036541</ArticleId></ArticleIdList></Reference><Reference><Citation>US FDA . Fact sheet for healthcare providers: emergency use authorization for paxlovid. [cited 2023 Dec 28] Available from: https://www.fda.gov/media/155050/download.</Citation></Reference><Reference><Citation>Hammond J, Leister-Tebbe H, Gardner A, et al. . Oral Nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397&#x2013;1408. doi:10.1056/NEJMoa2118542</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pmc">PMC8908851</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbel R, Wolff Sagy Y, Hoshen M, et al. . Nirmatrelvir use and severe Covid-19 outcomes during the omicron surge. N Engl J Med. 2022;387(9):790&#x2013;798. doi:10.1056/NEJMoa2204919</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2204919</ArticleId><ArticleId IdType="pmc">PMC9454652</ArticleId><ArticleId IdType="pubmed">36001529</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong CKH, Au ICH, Lau KTK, et al. . Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study. Lancet Infect Dis. 2022;22(12):1681&#x2013;1693. doi:10.1016/S1473-3099(22)00507-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00507-2</ArticleId><ArticleId IdType="pmc">PMC9401976</ArticleId><ArticleId IdType="pubmed">36029795</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y, Choi T, Al-Aly Z.. Association of treatment with nirmatrelvir and the risk of post-COVID-19 Condition. JAMA Intern Med. 2023;183(6):554&#x2013;564. doi:10.1001/jamainternmed.2023.0743</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2023.0743</ArticleId><ArticleId IdType="pmc">PMC10037200</ArticleId><ArticleId IdType="pubmed">36951829</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Wei Y, Hung CT, et al. . Association of nirmatrelvir-ritonavir with post-acute sequelae and mortality in patients admitted to hospital with COVID-19: a retrospective cohort study. Lancet Infect Dis. 2024 Oct;24(10):1130&#x2013;1140. doi:10.1016/S1473-3099(24)00217-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(24)00217-2</ArticleId><ArticleId IdType="pubmed">38710190</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannou GN, Berry K, Rajeevan N, et al. . Effectiveness of nirmatrelvir-ritonavir against the development of Post-COVID-19 conditions among U.S. veterans: a target trial emulation. Ann Intern Med. 2023;176(11):1486&#x2013;1497. doi:10.7326/M23-1394</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M23-1394</ArticleId><ArticleId IdType="pmc">PMC10620954</ArticleId><ArticleId IdType="pubmed">37903369</ArticleId></ArticleIdList></Reference><Reference><Citation>Durstenfeld MS, Peluso MJ, Lin F, et al. . Association of nirmatrelvir for acute SARS-CoV-2 infection with subsequent Long COVID symptoms in an observational cohort study. J Med Virol. 2024;96(1):e29333. doi:10.1002/jmv.29333</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.29333</ArticleId><ArticleId IdType="pmc">PMC10786003</ArticleId><ArticleId IdType="pubmed">38175151</ArticleId></ArticleIdList></Reference><Reference><Citation>Huh K, Kim YE, Bae GH, et al. . Vaccination and the risk of post-acute sequelae after COVID-19 in the omicron-predominant period. Clin Microbiol Infect. 2024;30(5):666&#x2013;673. doi:10.1016/j.cmi.2024.01.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2024.01.028</ArticleId><ArticleId IdType="pubmed">38331252</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynberg E, Han AX, Boyd A, et al. . The effect of SARS-CoV-2 vaccination on post-acute sequelae of COVID-19 (PASC): a prospective cohort study. Vaccine. 2022;40(32):4424&#x2013;4431. doi:10.1016/j.vaccine.2022.05.090</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2022.05.090</ArticleId><ArticleId IdType="pmc">PMC9170535</ArticleId><ArticleId IdType="pubmed">35725782</ArticleId></ArticleIdList></Reference><Reference><Citation>First shipment of COVID-19 oral drug Paxlovid distributed to HA for application. [cited 2023 Dec 8] Available from: https://www.info.gov.hk/gia/general/202203/15/P2022031500280.htm.</Citation></Reference><Reference><Citation>Boon SS, Wong MCS, Ng RWY, et al. . Seroprevalence of unidentified SARS-CoV-2 infection in Hong Kong during 3 pandemic waves. JAMA Netw Open. 2021;4(11):e2132923. doi:10.1001/jamanetworkopen.2021.32923</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.32923</ArticleId><ArticleId IdType="pmc">PMC8593764</ArticleId><ArticleId IdType="pubmed">34779848</ArticleId></ArticleIdList></Reference><Reference><Citation>Chong KC, Chan PK, Hung CT, et al. . Changes in all-cause and cause-specific excess mortality before and after the Omicron outbreak of COVID-19 in Hong Kong. J Glob Health. 2023;13:06017. doi:10.7189/jogh.13.06017</Citation><ArticleIdList><ArticleId IdType="doi">10.7189/jogh.13.06017</ArticleId><ArticleId IdType="pmc">PMC10143112</ArticleId><ArticleId IdType="pubmed">37114968</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam ICH, Wong CKH, Zhang R, et al. . Long-term post-acute sequelae of COVID-19 infection: a retrospective, multi-database cohort study in Hong Kong and the UK. EClinicalMedicine. 2023;60:102000. doi:10.1016/j.eclinm.2023.102000</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.102000</ArticleId><ArticleId IdType="pmc">PMC10173760</ArticleId><ArticleId IdType="pubmed">37197226</ArticleId></ArticleIdList></Reference><Reference><Citation>Daugherty SE, Guo Y, Heath K, et al. . Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. Br Med J. 2021;373:n1098. doi:10.1136/bmj.n1098</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1098</ArticleId><ArticleId IdType="pmc">PMC8132065</ArticleId><ArticleId IdType="pubmed">34011492</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan EYF, Yan VKC, Mok AHY, et al. . Effectiveness of molnupiravir and nirmatrelvir-ritonavir in hospitalized patients with COVID-19: a target trial emulation study. Ann Intern Med. 2023;176(4):505&#x2013;514. doi:10.7326/M22-3057</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M22-3057</ArticleId><ArticleId IdType="pmc">PMC10052319</ArticleId><ArticleId IdType="pubmed">36913693</ArticleId></ArticleIdList></Reference><Reference><Citation>HKHA . Interim recommendation on clinical management of adult cases with coronavirus Disease 2019 (COVID-19). [cited 2023 Dec 28] Available from: https://icidportal.ha.org.hk/Home/File?path&#x2009;=&#x2009;/Training%20Calendar/149/Interim%20Recommendation%20on%20Clinical%20Management%20of%20Adult%20Cases%20with%20COVID-19.pdf.</Citation></Reference><Reference><Citation>Yang B, Lin Y, Xiong W, et al. . Comparison of control and transmission of COVID-19 across epidemic waves in Hong Kong: an observational study. Lancet Reg Health West Pac. 2023 Nov 22;43:100969.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10700518</ArticleId><ArticleId IdType="pubmed">38076326</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung YYH, Lau EHY, Yin G, et al. . Effectiveness of vaccines and antiviral drugs in preventing severe and fatal COVID-19, Hong Kong. Emerg Infect Dis. 2024;30(1):70&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10756371</ArticleId><ArticleId IdType="pubmed">38040664</ArticleId></ArticleIdList></Reference><Reference><Citation>Catal&#xe0; M, Burn E, Rathod-Mistry T, et al. . Observational methods for COVID-19 vaccine effectiveness research: an empirical evaluation and target trial emulation. Int J Epidemiol. 2024 Feb 1;53(1):dyad138. doi:10.1093/ije/dyad138</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyad138</ArticleId><ArticleId IdType="pmc">PMC10859138</ArticleId><ArticleId IdType="pubmed">37833846</ArticleId></ArticleIdList></Reference><Reference><Citation>HKHA . Strategic service framework for palliative care. [cited 2024 Feb 21] Available from: https://www.ha.org.hk/haho/ho/ap/PCSSF_1.pdf.</Citation></Reference><Reference><Citation>Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat - Simul Comput. 2009;38(6):1228&#x2013;1234. doi:10.1080/03610910902859574</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03610910902859574</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch M, Tchetgen Tchetgen E, Cohen T.. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology. 2010 May;21(3):383&#x2013;388. doi:10.1097/EDE.0b013e3181d61eeb</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e3181d61eeb</ArticleId><ArticleId IdType="pmc">PMC3053408</ArticleId><ArticleId IdType="pubmed">20335814</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansournia MA, Nazemipour M.. Recommendations for accurate reporting in medical research statistics. Lancet. 2024;403(10427):611&#x2013;612. doi:10.1016/S0140-6736(24)00139-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(24)00139-9</ArticleId><ArticleId IdType="pubmed">38368003</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothman KJ, Greenland S, Lash TL. Modern epidemiology: Wolters Kluwer Health/Lippincott Williams &amp; Wilkins Philadelphia; 2008.</Citation></Reference><Reference><Citation>Knol MJ, VanderWeele TJ, Groenwold RH, et al. . Estimating measures of interaction on an additive scale for preventive exposures. Eur J Epidemiol. 2011;26(6):433&#x2013;438. doi:10.1007/s10654-011-9554-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10654-011-9554-9</ArticleId><ArticleId IdType="pmc">PMC3115067</ArticleId><ArticleId IdType="pubmed">21344323</ArticleId></ArticleIdList></Reference><Reference><Citation>Seb&#x151;k S, Gyires K.. Long COVID and possible preventive options. Inflammopharmacology. 2023;31(6):2807&#x2013;2817. doi:10.1007/s10787-023-01204-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-023-01204-1</ArticleId><ArticleId IdType="pmc">PMC10692252</ArticleId><ArticleId IdType="pubmed">37344737</ArticleId></ArticleIdList></Reference><Reference><Citation>Vijayasingham L, Bischof E, Wolfe J.. Sex-disaggregated data in COVID-19 vaccine trials. Lancet. 2021;397(10278):966&#x2013;967. doi:10.1016/S0140-6736(21)00384-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00384-6</ArticleId><ArticleId IdType="pmc">PMC7952097</ArticleId><ArticleId IdType="pubmed">33684351</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai F, Tomasoni D, Falcinella C, et al. . Female gender is associated with long COVID syndrome: a prospective cohort study. Clin Microbiol Infect. 2022;28(4):611, e9-.e16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8575536</ArticleId><ArticleId IdType="pubmed">34763058</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen K, Ren S, Heath K, et al. . Risk of persistent and new clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-CoV-2 infection: retrospective cohort study. Br Med J. 2022;376:e068414.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8828141</ArticleId><ArticleId IdType="pubmed">35140117</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau JJ, Cheng SMS, Leung K, et al. . Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population. Nat Med. 2023;29(2):348&#x2013;357. doi:10.1038/s41591-023-02219-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-023-02219-5</ArticleId><ArticleId IdType="pmc">PMC9941049</ArticleId><ArticleId IdType="pubmed">36652990</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei Y, Jia KM, Zhao S, et al. . Estimation of vaccine effectiveness of CoronaVac and BNT162b2 against severe outcomes over time among patients with SARS-CoV-2 Omicron. JAMA Netw Open. 2023;6(2):e2254777. doi:10.1001/jamanetworkopen.2022.54777</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.54777</ArticleId><ArticleId IdType="pmc">PMC9898822</ArticleId><ArticleId IdType="pubmed">36735253</ArticleId></ArticleIdList></Reference><Reference><Citation>Knol MJ, VanderWeele TJ.. Recommendations for presenting analyses of effect modification and interaction. Int J Epidemiol. 2012;41(2):514&#x2013;520. doi:10.1093/ije/dyr218</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyr218</ArticleId><ArticleId IdType="pmc">PMC3324457</ArticleId><ArticleId IdType="pubmed">22253321</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>